FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295779503> ?p ?o ?g. }

• W4295779503 endingPage "106165" @default.
• W4295779503 startingPage "106165" @default.
• W4295779503 abstract "The chemotype of arylsulfonamide derivatives of cyclic arylguanidines is a source of molecules with valuable biological activities, including antimicrobial and antitumor properties. The methods of the synthesis presented in the literature are characterized with low selectivity and high environmental nuisance. In this publication, we present a developed alternative and earlier undescribed pathway C, for the synthesis of arylsulfonamide derivatives of cyclic arylguanidines (N-(1H-arylimidazol-2-yl)arylsulfonamides and N-(1,4-dihydroquinazolin-2-yl)arylsulfonamides), including reaction between 2-(methylsulfanyl)-benzimidazole or 2-(methylsulfanyl)-3,4-dihydroquinazoline with arylsulfonamides. We also optimized previously reported methods; A (reaction of 2-aminobenzimidazole or 2-amino-3,4-dihydroquinazoline with arylsulfonyl chlorides) and B (reaction of dimethyl-(arylsulfonyl)carbonodithioimidate with aryldiamines). The conducted research allowed achieving two independent ecological and quick methods of obtaining the desired products. We used ecological methods of ultrasound-assisted or microwave synthesis, solvent-free reactions and agreen reaction environment. In both pathways, it has proven advantageous to use H2O as the solvent and K2CO3 (1 or 3 equivalent) as the basic agent. In the sonochemical variant, the efficiency reached B: 37-89 %, C: 90 % in 60 min (P = 80 W and f = 40 kHz), while in the microwave synthesis it was B: 38-74 %, C: 63-85 % in 0.5-4 min (P = 50 W). Path A led to a complementary substitution product (i.e. 1-(arylsulfonyl)-1H-benzimidazol-2-amine or 1-(arylsulfonyl)-1,4-dihydroquinazolin-2-amine). We obtained a small group of compounds that were tested for cytotoxicity. The 10f (N-(1,4-dihydroquinazolin-2-yl)naphthalene-1-sulfonamide) showed cytotoxic activity towards human astrocytoma cell line 1321 N1. The calculated IC50 value was 8.22 µM at 24 h timepoint (doxorubicin suppressed 1321 N1 cell viability with IC50 of 1.1 µM). The viability of the cells exposed to 10f for 24 h dropped to 48.0 % compared to vehicle control, while the cells treated with doxorubicin experienced decline to 47.5 %. We assessed its potential usefulness in pharmacotherapy in the ADMET study, confirming its ability to cross the blood-brain barrier (Pe = 5.0 ± 1.5 × 10-6 cm/s) and the safety of its potential use in terms of DDI and hepatotoxicity." @default.
• W4295779503 created "2022-09-15" @default.
• W4295779503 creator A5008442367 @default.
• W4295779503 creator A5008724133 @default.
• W4295779503 creator A5052318171 @default.
• W4295779503 creator A5052622508 @default.
• W4295779503 creator A5069944142 @default.
• W4295779503 creator A5081072732 @default.
• W4295779503 date "2022-11-01" @default.
• W4295779503 modified "2023-09-25" @default.
• W4295779503 title "Eco-friendly methods of synthesis and preliminary biological evaluation of sulfonamide derivatives of cyclic arylguanidines" @default.
• W4295779503 cites W1982661003 @default.
• W4295779503 cites W1986370995 @default.
• W4295779503 cites W1990664237 @default.
• W4295779503 cites W1995689370 @default.
• W4295779503 cites W1995763307 @default.
• W4295779503 cites W2000815209 @default.
• W4295779503 cites W2010932849 @default.
• W4295779503 cites W2010992694 @default.
• W4295779503 cites W2015811644 @default.
• W4295779503 cites W2016575780 @default.
• W4295779503 cites W2022079874 @default.
• W4295779503 cites W2032961309 @default.
• W4295779503 cites W2043509228 @default.
• W4295779503 cites W2052844753 @default.
• W4295779503 cites W2058363175 @default.
• W4295779503 cites W2059724811 @default.
• W4295779503 cites W2060438885 @default.
• W4295779503 cites W2071555876 @default.
• W4295779503 cites W2072692396 @default.
• W4295779503 cites W2077332810 @default.
• W4295779503 cites W2077796804 @default.
• W4295779503 cites W2086108095 @default.
• W4295779503 cites W2090365405 @default.
• W4295779503 cites W2098358868 @default.
• W4295779503 cites W2108583965 @default.
• W4295779503 cites W2135732933 @default.
• W4295779503 cites W2139933808 @default.
• W4295779503 cites W2150697053 @default.
• W4295779503 cites W2162011385 @default.
• W4295779503 cites W2320931848 @default.
• W4295779503 cites W2322016289 @default.
• W4295779503 cites W2325008286 @default.
• W4295779503 cites W2330035135 @default.
• W4295779503 cites W2396930286 @default.
• W4295779503 cites W2472055225 @default.
• W4295779503 cites W2531613256 @default.
• W4295779503 cites W2593436234 @default.
• W4295779503 cites W2753063582 @default.
• W4295779503 cites W2757649528 @default.
• W4295779503 cites W2774581676 @default.
• W4295779503 cites W2884716408 @default.
• W4295779503 cites W2892778858 @default.
• W4295779503 cites W2952516108 @default.
• W4295779503 cites W2957902649 @default.
• W4295779503 cites W3003025448 @default.
• W4295779503 cites W3044368832 @default.
• W4295779503 cites W3207690765 @default.
• W4295779503 cites W4288046150 @default.
• W4295779503 doi "https://doi.org/10.1016/j.ultsonch.2022.106165" @default.
• W4295779503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36183548" @default.
• W4295779503 hasPublicationYear "2022" @default.
• W4295779503 type Work @default.
• W4295779503 citedByCount "3" @default.
• W4295779503 countsByYear W42957795032022 @default.
• W4295779503 countsByYear W42957795032023 @default.
• W4295779503 crossrefType "journal-article" @default.
• W4295779503 hasAuthorship W4295779503A5008442367 @default.
• W4295779503 hasAuthorship W4295779503A5008724133 @default.
• W4295779503 hasAuthorship W4295779503A5052318171 @default.
• W4295779503 hasAuthorship W4295779503A5052622508 @default.
• W4295779503 hasAuthorship W4295779503A5069944142 @default.
• W4295779503 hasAuthorship W4295779503A5081072732 @default.
• W4295779503 hasBestOaLocation W42957795031 @default.
• W4295779503 hasConcept C118792377 @default.
• W4295779503 hasConcept C131779359 @default.
• W4295779503 hasConcept C161790260 @default.
• W4295779503 hasConcept C178790620 @default.
• W4295779503 hasConcept C185592680 @default.
• W4295779503 hasConcept C21951064 @default.
• W4295779503 hasConcept C2778484023 @default.
• W4295779503 hasConcept C2780471494 @default.
• W4295779503 hasConcept C2781039511 @default.
• W4295779503 hasConceptScore W4295779503C118792377 @default.
• W4295779503 hasConceptScore W4295779503C131779359 @default.
• W4295779503 hasConceptScore W4295779503C161790260 @default.
• W4295779503 hasConceptScore W4295779503C178790620 @default.
• W4295779503 hasConceptScore W4295779503C185592680 @default.
• W4295779503 hasConceptScore W4295779503C21951064 @default.
• W4295779503 hasConceptScore W4295779503C2778484023 @default.
• W4295779503 hasConceptScore W4295779503C2780471494 @default.
• W4295779503 hasConceptScore W4295779503C2781039511 @default.
• W4295779503 hasFunder F4320322511 @default.
• W4295779503 hasFunder F4320337160 @default.
• W4295779503 hasLocation W42957795031 @default.
• W4295779503 hasLocation W42957795032 @default.
• W4295779503 hasLocation W42957795033 @default.
• W4295779503 hasOpenAccess W4295779503 @default.

• next